Skip to main content
. Author manuscript; available in PMC: 2021 Sep 2.
Published in final edited form as: Ann Oncol. 2020 Mar 21;31(6):798–806. doi: 10.1016/j.annonc.2020.03.287

Figure 2. PFS by tumour PD-L1 expression status (BICR; intention-to-treat population).a.

Figure 2.

BICR, blinded independent central review; CI, confidence interval; DCO, data cutoff; Durva., durvalumab; HR, hazard ratio; mo, months; NR, not reached; PD-L1, programmed death-ligand 1; PFS, progression-free survival; TC, tumour cell; UNK, unknown.

a DCO was 13 February 2017 (DCO for the primary analysis of PFS): median duration of follow-up of 14.5 months (range, 0.2–29.9).